Featuring perspectives from Dr Nicoletta Colombo, Dr Gottfried E Konecny, Dr Alexander B Olawaiye and Dr Shannon N Westin, moderated by Dr Westin, including the following topics:

• Case: A woman in her early 70s with endometrioid carcinoma of the ovary and a large solitary brain metastasis after primary debulking surgery and adjuvant carboplatin/paclitaxel — Professor Jonathan A Ledermann (0:00)

CME information and select publications

Featuring perspectives from Dr Nicoletta Colombo, Dr Gottfried E Konecny, Dr Alexander B Olawaiye and Dr Shannon N Westin, moderated by Dr Westin, including the following topics:

• Case: A woman in her late 60s with a germline BRCA2 mutation and heavily pretreated ovarian cancer receives weekly nab paclitaxel and relacorilant — Angeles Alvarez Secord, MD, MHSc (0:00)

CME information and select publications

Featuring an interview with Prof Karim Fizazi, including the following topics:

• Perspectives on the PROTEUS Phase III trial evaluating the addition of apalutamide to standard therapy for high-risk localized prostate cancer (0:00)
• Mechanism of action of opevesostat and potential role in castration-resistant prostate cancer with androgen receptor mutations (15:37)
• Perspectives on alpha- and beta-emitting radiopharmaceuticals in the treatment of prostate cancer (22:47)
• Novel antibody-drug conjugates and proteolysis-targeting chimeras (30:43)
• Treatment approaches for metastatic hormone-sensitive prostate cancer — de novo symptomatic presentation versus PSMA-only metastatic recurrence after local therapy (34:51)
• Role of intermittent therapy in the treatment of prostate cancer (38:48)
• Treatment intensification approaches in prostate cancer (41:38)
• Case: A man in his late 60s with de novo PSMA PET-positive metastatic castration-sensitive prostate cancer (45:25)

CME information and select publications

Featuring a slide presentation and related discussion from Prof Karim Fizazi, including the following topics:

• PROTEUS Phase III trial evaluating the addition of apalutamide to standard therapy in high-risk localized prostate cancer (0:00)
• Time to testosterone recovery during treatment suspension in the Phase III EMBARK trial of enzalutamide and leuprolide in nonmetastatic prostate cancer (5:05)
• Radiographic progression-free survival subgroup analysis in the PSMAddition Phase III trial of 177Lu-PSMA-617 in metastatic hormone-sensitive prostate cancer (6:58)
• TALAPRO-3: Efficacy of talazoparib and enzalutamide in metastatic hormone-sensitive prostate cancer harboring homologous recombination repair gene alterations (8:16)
• Phase I/II PETRANHA study of novel PARP inhibitor saruparib in metastatic hormone-sensitive prostate cancer (10:52)
• Phase II A-DREAM trial of androgen deprivation therapy interruption in patients with metastatic hormone-sensitive prostate cancer responding to androgen receptor pathway inhibitor (13:23)
• Overall survival by duration of enzalutamide treatment received in the Phase III ARCHES trial (15:21)
• Efficacy of capivasertib and abiraterone in the Phase III CAPItello-281 trial for patients with PTEN-deficient metastatic hormone-sensitive prostate cancer (16:24)
• Phase I AcTION study of 225Ac-PSMA-617 in patients with metastatic castration-resistant prostate cancer (mCRPC) with or without prior 177Lu-PSMA radioligand therapy (18:16)
• Phase III PSMAfore trial of 177Lu-PSMA-617 in progressive mCRPC; ongoing Phase III trials of radioligands in mCRPC (19:54)
• Ongoing Phase III OMAHA-004 trial of CYP11 inhibitor opevesostat versus next-generation hormonal agent switch in patients with mCRPC and 1 prior next-generation hormonal agent (23:14)

CME information and select publications

Featuring perspectives from Prof Susana Banerjee, including the following topics:

• Case: A woman in her mid 50s with multiregimen-recurrent low-grade serous ovarian cancer and a KRAS G12V mutation who receives avutometinib/defactinib with response, asymptomatic creatine phosphokinase elevation and mild facial rash — Dr Stover (0:00)
• Case: A woman in her early 30s with recurrent metastatic low-grade serous ovarian cancer, originally offered hospice due to poor condition, who receives avutometinib/defactinib with an excellent response — Dr Hussein (7:58)
• Case: A woman in her late 30s with multiregimen-recurrent folate receptor alpha-positive low-grade serous ovarian cancer (HER2 IHC 2+) who receives mirvetuximab soravtansine — Dr Cobb (18:21)

CME information and select publications

Featuring perspectives from Prof Susana Banerjee, including the following topics:

• Overview of the biology and treatment of low-grade serous ovarian cancer (0:00)
• Mechanism of action of avutometinib/defactinib (10:16)
• RAMP 201 Trial: Avutometinib/defactinib in recurrent low-grade serous ovarian cancer (14:32)
• Ongoing clinical trials in low-grade serous ovarian cancer (27:57)

CME information and select publications

Featuring perspectives from Dr Spencer Bachow, Dr Bhavana (Tina) Bhatnagar, Dr Jennifer Crombie, Dr Manali Kamdar and Ms Alexandra Lynch, co-moderated by Dr Bachow and Dr Bhatnagar, including the following topics:

• Introduction and Overview of Bispecific Antibodies in the Clinic (0:00)
• Current and Future Role of Bispecific Antibodies in Non-Hodgkin Lymphoma — Dr Kamdar (15:58)
• Case: A man in his early 60s with diffuse large B-cell lymphoma (DLBCL) receives glofitamab (42:40)
• Case: A woman in her early 80s with follicular lymphoma (FL) receives mosunetuzumab (51:50)
• Mitigation and Management of Cytokine Release Syndrome (CRS) and Other Toxicities Associated with Bispecific Antibodies — Dr Crombie (1:00:39)
• Case: A woman in her early 80s with DLBCL receives glofitamab (1:18:50)
• Case: A woman in her early 70s with FL receives epcoritamab (1:26:38)
• Outpatient CRS Management in B-Cell Lymphomas — Ms Lynch (1:29:28)
• Case: A woman in her late 40s with FL receives epcoritamab (1:38:33)
• Case: A man in his early 70s with mantle cell lymphoma receives mosunetuzumab (1:46:26)

CME information and select publications

Featuring a slide presentation from Dr Julia Rotow, including the following topics:

• Rationale and potential clinical role of PD-1/PD-L1 x vascular endothelial growth factor (VEGF) bispecific antibodies in the treatment of non-small cell lung cancer (NSCLC) (0:00)
• Key findings from the Phase III HARMONi-6 study; ongoing Phase III HARMONi-3 study (5:12)
• Key findings from the Phase III HARMONi-2 study; ongoing Phase III HARMONi-7 study (9:59)
• Clinician insights about the potential role of ivonescimab in the front-line setting (12:02)
• Impetus for investigating ivonescimab in the relapsed/refractory (R/R) EGFR-mutant setting (14:01)
• Key findings from the Phase III HARMONi-A and HARMONi studies (16:07)
• Clinician insights about the potential role of ivonescimab in the treatment of R/R EGFR-mutant NSCLC; other novel PD-1/PD-L1 x VEGF bispecific antibodies under investigation (20:30)

CME information and select publications